Latest Commercialisation Strategies News

Amaero Ltd reports solid June quarter revenue and signs a pivotal five-year exclusive supply agreement with Velo3D, underpinning its growth outlook and updated EBITDA guidance for FY2027.

Metallium Ltd has completed a A$50 million institutional raise, secured a Texas site, and validated its commercial Flash Joule Heating reactor, setting the stage for its first U.S. metals recovery plant commissioning by year-end 2025.

ImpediMed has doubled its US unit sales in Q4 FY25, achieving a record total contract value and securing an additional $5 million tranche under its growth capital facility.

Archer Materials advances its quantum computing and medical diagnostics technologies, extending key partnerships and forming a new advisory board while maintaining a strong cash position to fuel development.

InteliCare has launched a three-month trial of its AI-powered platform at mecwacare’s Trescowthick Centre, marking a significant step in its commercialisation strategy with a leading aged care provider.

Echo IQ has secured a pivotal reseller agreement with US-based SARC MedIQ, unlocking access to over 300 healthcare facilities and accelerating adoption of its AI-driven EchoSolv AS technology across the American cardiology landscape.

Orthocell Limited has posted a record quarterly revenue of A$2.73 million, driven by strong Australian sales of its nerve repair product Remplir™, with US market expansion poised to accelerate in FY26.

First Graphene Limited has secured two significant orders totaling approximately A$165,000 for its PureGRAPH graphene products, signaling growing market acceptance and supporting its FY25-26 sales outlook.

Astral Resources has released a compelling Pre-Feasibility Study for its Mandilla Gold Project in Western Australia, outlining a 19-year mine life with robust economics and a maiden ore reserve of 1.1 million ounces. The study sets the stage for a Definitive Feasibility Study targeted for mid-2026.

Rhythm Biosciences has regained NATA accreditation for its geneType laboratory, a key step toward commercialising its ColoSTAT® cancer risk test as an in-house diagnostic.

Proteomics International has launched PromarkerD, a pioneering blood test that predicts diabetic kidney disease years before symptoms, marking its entry into the vast US healthcare market.

Hazer Group Limited has opened a $2 million underwritten Share Purchase Plan, offering eligible shareholders in Australia and New Zealand the chance to buy shares at the same price as a recent institutional placement. The funds will support the commercialisation of its methane reactor technology and synthetic graphite development.